3 results
The primary objective of this study is to evaluate the long-term safety and tolerability of the TAK-491CLD FDC in comparison to the OLM/HCTZ FDC in hypertensive subjects with moderate renal impairment.
Primary ObjectiveTo assess the efficacy of furmonertinib compared to platinum-based chemotherapy using progression-free survival (PFS) in previously untreated patients with locally advanced or metastatic non-squamous NSCLC with EGFR exon 20…
Stage 1 Primary ObjectiveTo evaluate the safety and tolerability, determine the expansion dose, and characterize dose-limiting toxicities (DLTs) of escalating doses of furmonertinib administered daily to patients with locally advanced or metastatic…